159 related articles for article (PubMed ID: 36838656)
1. Kavalactone Kawain Impedes Urothelial Tumorigenesis in UPII-Mutant Ha-Ras Mice via Inhibition of mTOR Signaling and Alteration of Cancer Metabolism.
Liu Z; Song L; Xie J; Wu XR; Gin GE; Wang B; Uchio E; Zi X
Molecules; 2023 Feb; 28(4):. PubMed ID: 36838656
[TBL] [Abstract][Full Text] [Related]
2. Chemoprevention of Urothelial Cell Carcinoma Tumorigenesis by Dietary Flavokawain A in UPII-Mutant Ha-ras Transgenic Mice.
Liu Z; Song L; Xie J; Simoneau AR; Uchio E; Zi X
Pharmaceutics; 2022 Feb; 14(3):. PubMed ID: 35335874
[TBL] [Abstract][Full Text] [Related]
3. Kava chalcone, flavokawain A, inhibits urothelial tumorigenesis in the UPII-SV40T transgenic mouse model.
Liu Z; Xu X; Li X; Liu S; Simoneau AR; He F; Wu XR; Zi X
Cancer Prev Res (Phila); 2013 Dec; 6(12):1365-75. PubMed ID: 24121102
[TBL] [Abstract][Full Text] [Related]
4. The Potent Anti-Tumor Effects of Rhodiola Drinking Are Associated with the Inhibition of the mTOR Pathway and Modification of Tumor Metabolism in the UPII-Mutant Ha-Ras Model.
Liu Z; Yokoyama NN; Song L; Xie J; Sadeghi Z; Wu YX; Yee S; Wu XR; Wang B; Uchio E; Zi X
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370698
[No Abstract] [Full Text] [Related]
5. p53-stabilizing agent CP-31398 prevents growth and invasion of urothelial cancer of the bladder in transgenic UPII-SV40T mice.
Madka V; Zhang Y; Li Q; Mohammed A; Sindhwani P; Lightfoot S; Wu XR; Kopelovich L; Rao CV
Neoplasia; 2013 Aug; 15(8):966-74. PubMed ID: 23908596
[TBL] [Abstract][Full Text] [Related]
6. High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with ∼240-Fold Higher Drug Concentration in Urine than Serum.
Liu Z; Yokoyama NN; Blair CA; Li X; Avizonis D; Wu XR; Uchio E; Youssef R; McClelland M; Pollak M; Zi X
Mol Cancer Ther; 2016 Mar; 15(3):430-8. PubMed ID: 26921394
[TBL] [Abstract][Full Text] [Related]
7. Chemoprevention of urothelial cell carcinoma growth and invasion by the dual COX-LOX inhibitor licofelone in UPII-SV40T transgenic mice.
Madka V; Mohammed A; Li Q; Zhang Y; Patlolla JM; Biddick L; Lightfoot S; Wu XR; Steele V; Kopelovich L; Rao CV
Cancer Prev Res (Phila); 2014 Jul; 7(7):708-16. PubMed ID: 24795386
[TBL] [Abstract][Full Text] [Related]
8. Targeting mTOR and p53 Signaling Inhibits Muscle Invasive Bladder Cancer In Vivo.
Madka V; Mohammed A; Li Q; Zhang Y; Biddick L; Patlolla JM; Lightfoot S; Towner RA; Wu XR; Steele VE; Kopelovich L; Rao CV
Cancer Prev Res (Phila); 2016 Jan; 9(1):53-62. PubMed ID: 26577454
[TBL] [Abstract][Full Text] [Related]
9. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
10. Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation.
Zhang ZT; Pak J; Huang HY; Shapiro E; Sun TT; Pellicer A; Wu XR
Oncogene; 2001 Apr; 20(16):1973-80. PubMed ID: 11360181
[TBL] [Abstract][Full Text] [Related]
11. Significance of 4E-binding protein 1 as a therapeutic target for invasive urothelial carcinoma of the bladder.
Nishikawa M; Miyake H; Behnsawy HM; Fujisawa M
Urol Oncol; 2015 Apr; 33(4):166.e9-15. PubMed ID: 25618298
[TBL] [Abstract][Full Text] [Related]
12. p53 deficiency provokes urothelial proliferation and synergizes with activated Ha-ras in promoting urothelial tumorigenesis.
Gao J; Huang HY; Pak J; Cheng J; Zhang ZT; Shapiro E; Pellicer A; Sun TT; Wu XR
Oncogene; 2004 Jan; 23(3):687-96. PubMed ID: 14737103
[TBL] [Abstract][Full Text] [Related]
13. Urothelial tumor initiation requires deregulation of multiple signaling pathways: implications in target-based therapies.
Zhou H; Huang HY; Shapiro E; Lepor H; Huang WC; Mohammadi M; Mohr I; Tang MS; Huang C; Wu XR
Carcinogenesis; 2012 Apr; 33(4):770-80. PubMed ID: 22287562
[TBL] [Abstract][Full Text] [Related]
14. Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder.
Sun CH; Chang YH; Pan CC
Histopathology; 2011 Jun; 58(7):1054-63. PubMed ID: 21707707
[TBL] [Abstract][Full Text] [Related]
15. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of epidermal growth factor receptor in urothelium elicits urothelial hyperplasia and promotes bladder tumor growth.
Cheng J; Huang H; Zhang ZT; Shapiro E; Pellicer A; Sun TT; Wu XR
Cancer Res; 2002 Jul; 62(14):4157-63. PubMed ID: 12124355
[TBL] [Abstract][Full Text] [Related]
17. Flavokawain A, a novel chalcone from kava extract, induces apoptosis in bladder cancer cells by involvement of Bax protein-dependent and mitochondria-dependent apoptotic pathway and suppresses tumor growth in mice.
Zi X; Simoneau AR
Cancer Res; 2005 Apr; 65(8):3479-86. PubMed ID: 15833884
[TBL] [Abstract][Full Text] [Related]
18. The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers.
Makhlin I; Zhang J; Long CJ; Devarajan K; Zhou Y; Klein-Szanto AJ; Huang M; Chernoff J; Boorjian SA
BJU Int; 2011 Jul; 108(2 Pt 2):E84-90. PubMed ID: 21050361
[TBL] [Abstract][Full Text] [Related]
19. Identification of genes correlated with early-stage bladder cancer progression.
Stone R; Sabichi AL; Gill J; Lee IL; Adegboyega P; Dai MS; Loganantharaj R; Trutschl M; Cvek U; Clifford JL
Cancer Prev Res (Phila); 2010 Jun; 3(6):776-86. PubMed ID: 20501863
[TBL] [Abstract][Full Text] [Related]
20. S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer.
Nawroth R; Stellwagen F; Schulz WA; Stoehr R; Hartmann A; Krause BJ; Gschwend JE; Retz M
PLoS One; 2011; 6(11):e27509. PubMed ID: 22110663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
